Mirum Pharmaceuticals, INC Form 4 insider transactions

SVP, Global Controller of Mirum Pharmaceuticals, Jolanda Howe, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Christopher Peetz, CEO of Mirum Pharmaceuticals, reports the acquisition and disposal of company stock, including the vesting of restricted stock units and sales to cover tax obligations.

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, received stock options and restricted stock units as part of her compensation package.

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, was granted stock options and restricted stock units on January 21, 2025.

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkhot, was granted stock options and restricted stock units on January 21, 2025.

Peter Radovich, President and COO of Mirum Pharmaceuticals, acquired stock options and restricted stock units on January 21, 2025, according to a recent SEC filing.

Mirum Pharmaceuticals CEO, Christopher Peetz, acquired stock options, restricted stock units, and performance restricted stock units on January 21, 2025.

Mirum Pharmaceuticals' Chief Medical Officer, Joanne Quan, exercised stock options and sold shares to cover tax obligations.

Peter Radovich, President and COO of Mirum Pharmaceuticals, sold 1,998 shares of common stock to cover tax obligations related to vesting restricted stock units.

Mirum Pharmaceuticals CEO, Christopher Peetz, sold 7,489 shares of common stock to cover tax obligations related to vesting restricted stock units.

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

A Mirum Pharmaceuticals executive, Jolanda Howe, exercised stock options and sold shares on November 14, 2024.

Joanne Quan, Chief Medical Officer of Mirum Pharmaceuticals, acquired 118 shares of common stock through the company's Employee Stock Purchase Plan.

Mirum Pharmaceuticals' Chief Financial Officer, Eric Bjerkhot, acquired 475 shares of common stock through the company's Employee Stock Purchase Plan.

Mirum Pharmaceuticals CEO, Christopher Peetz, acquired 65 shares of common stock through the company's Employee Stock Purchase Plan on November 8, 2024.

Director Michael G. Grey of Mirum Pharmaceuticals gifted 102,788 shares of common stock to The Children's Hospital of Philadelphia Foundation on September 27, 2024.

Director Patrick J. Heron reports acquiring 115 shares of Mirum Pharmaceuticals common stock at $37.40 per share, while also indirectly holding significant shares through Frazier Life Sciences partnerships.

Eric Bjerkholt, CFO of Mirum Pharmaceuticals, reports the disposition of 18,334 common stock shares and the corresponding vesting of restricted stock units on September 11, 2024.

Director Patrick Heron reports purchasing 230 shares of Mirum Pharmaceuticals through Frazier Life Sciences X, L.P. at a weighted average price of $41.5783 on September 6, 2024.

Mirum Pharmaceuticals CEO Christopher Peetz exercised stock options to acquire 34,013 shares of common stock at a price of $2.936 per share on July 23, 2024.

Jolanda Howe, SVP, Global Controller of Mirum Pharmaceuticals, reports the acquisition and disposal of common stock and restricted stock units on July 1st and 2nd, 2024.

Pamela Vig, Chief Scientific Officer of Mirum Pharmaceuticals, exercised stock options and sold shares of common stock on June 24, 2024, under a pre-arranged Rule 10b5-1 trading plan.

A Form 4 filing reveals that Michael G. Grey, a director at Mirum Pharmaceuticals, acquired stock options and deferred stock units on June 5, 2024.

Director Timothy Walbert reports acquisition of stock options and restricted stock units in Mirum Pharmaceuticals.

Director Lon Cardon reports acquisition of stock options and restricted stock units in Mirum Pharmaceuticals.

Director Laura Brege reports acquisition of stock options and restricted stock units in Mirum Pharmaceuticals.

Director Patrick J. Heron acquired stock options and restricted stock units in Mirum Pharmaceuticals, Inc. on June 5, 2024, according to a Form 4 filing.

Director Laurent Fischer reports acquisition of stock options and deferred stock units in Mirum Pharmaceuticals.

Director Saira Ramasastry of Mirum Pharmaceuticals exercised stock options and sold 5,000 shares of common stock on June 5, 2024.

Director William Fairey of Mirum Pharmaceuticals acquired stock options for 8,779 shares and 5,703 restricted stock units on June 5, 2024.